vs
Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and SenesTech, Inc. (SNES). Click either name above to swap in a different company.
InMed Pharmaceuticals Inc. is the larger business by last-quarter revenue ($820.2K vs $421.0K, roughly 1.9× SenesTech, Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -428.5%, a 181.2% gap on every dollar of revenue. On growth, SenesTech, Inc. posted the faster year-over-year revenue change (-16.0% vs -26.2%). Over the past eight quarters, SenesTech, Inc.'s revenue compounded faster (0.7% CAGR vs -16.4%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
SenesTech, Inc. is an agricultural biotechnology life-sciences company, specializing in fertility management as a form of pest control. The company's primary product, ContraPest is designed to make brown and black rats infertile. SenesTech is headquartered in Phoenix, Arizona.
INM vs SNES — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $820.2K | $421.0K |
| Net Profit | $-2.0M | $-1.8M |
| Gross Margin | 22.5% | 55.3% |
| Operating Margin | -247.3% | -446.8% |
| Net Margin | -247.3% | -428.5% |
| Revenue YoY | -26.2% | -16.0% |
| Net Profit YoY | 21.2% | -43.7% |
| EPS (diluted) | $-0.51 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $820.2K | $421.0K | ||
| Q3 25 | $1.1M | $690.0K | ||
| Q2 25 | $1.3M | $625.0K | ||
| Q1 25 | $1.3M | $485.0K | ||
| Q4 24 | $1.1M | $501.0K | ||
| Q3 24 | $1.3M | $482.0K | ||
| Q2 24 | $1.3M | $459.0K | ||
| Q1 24 | $1.2M | $415.0K |
| Q4 25 | $-2.0M | $-1.8M | ||
| Q3 25 | $-1.7M | $-1.3M | ||
| Q2 25 | $-1.8M | $-1.6M | ||
| Q1 25 | $-2.1M | $-1.7M | ||
| Q4 24 | $-2.6M | $-1.3M | ||
| Q3 24 | $-1.7M | $-1.5M | ||
| Q2 24 | $-1.9M | $-1.6M | ||
| Q1 24 | $-1.7M | $-1.8M |
| Q4 25 | 22.5% | 55.3% | ||
| Q3 25 | 36.0% | 62.8% | ||
| Q2 25 | 44.2% | 65.4% | ||
| Q1 25 | 13.9% | 64.5% | ||
| Q4 24 | 41.5% | 60.9% | ||
| Q3 24 | 39.0% | 65.4% | ||
| Q2 24 | 36.3% | 54.2% | ||
| Q1 24 | 24.7% | 32.5% |
| Q4 25 | -247.3% | -446.8% | ||
| Q3 25 | -154.2% | -195.2% | ||
| Q2 25 | -137.1% | -258.2% | ||
| Q1 25 | -168.1% | -342.9% | ||
| Q4 24 | -231.6% | -250.9% | ||
| Q3 24 | -132.7% | -321.0% | ||
| Q2 24 | -150.5% | -349.0% | ||
| Q1 24 | -146.9% | -444.1% |
| Q4 25 | -247.3% | -428.5% | ||
| Q3 25 | -154.2% | -188.1% | ||
| Q2 25 | -137.1% | -258.6% | ||
| Q1 25 | -168.1% | -343.3% | ||
| Q4 24 | -231.6% | -250.5% | ||
| Q3 24 | -132.7% | -313.9% | ||
| Q2 24 | -151.0% | -345.1% | ||
| Q1 24 | -146.9% | -441.4% |
| Q4 25 | $-0.51 | $0.48 | ||
| Q3 25 | $-0.44 | $-0.28 | ||
| Q2 25 | $-0.07 | $-0.87 | ||
| Q1 25 | $-1.94 | $-1.28 | ||
| Q4 24 | $-3.64 | $-0.15 | ||
| Q3 24 | $-2.71 | $-2.07 | ||
| Q2 24 | $2.39 | $-3.08 | ||
| Q1 24 | $-3.58 | $-3.56 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $8.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $9.6M |
| Total Assets | $11.2M | $12.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $8.6M | ||
| Q3 25 | $9.4M | $10.2M | ||
| Q2 25 | $11.1M | $6.1M | ||
| Q1 25 | $4.7M | $1.7M | ||
| Q4 24 | $3.5M | $1.3M | ||
| Q3 24 | $5.6M | $2.5M | ||
| Q2 24 | $6.6M | $2.0M | ||
| Q1 24 | — | $3.6M |
| Q4 25 | $9.6M | $9.6M | ||
| Q3 25 | $11.6M | $11.3M | ||
| Q2 25 | $13.4M | $7.0M | ||
| Q1 25 | $7.0M | $2.9M | ||
| Q4 24 | $6.2M | $2.5M | ||
| Q3 24 | $8.4M | $3.7M | ||
| Q2 24 | $9.2M | $3.1M | ||
| Q1 24 | $11.1M | $4.6M |
| Q4 25 | $11.2M | $12.8M | ||
| Q3 25 | $13.4M | $14.6M | ||
| Q2 25 | $15.6M | $10.4M | ||
| Q1 25 | $9.3M | $3.6M | ||
| Q4 24 | $8.5M | $3.3M | ||
| Q3 24 | $10.5M | $4.4M | ||
| Q2 24 | $11.8M | $4.0M | ||
| Q1 24 | — | $5.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $-1.7M |
| Free Cash FlowOCF − Capex | — | $-1.7M |
| FCF MarginFCF / Revenue | — | -398.3% |
| Capex IntensityCapex / Revenue | — | 3.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-5.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $-1.7M | ||
| Q3 25 | $-1.6M | $-1.4M | ||
| Q2 25 | $-1.8M | $-1.1M | ||
| Q1 25 | $-1.7M | $-1.6M | ||
| Q4 24 | $-2.5M | $-1.2M | ||
| Q3 24 | $-1.8M | $-1.4M | ||
| Q2 24 | $-1.0M | $-1.6M | ||
| Q1 24 | $-1.9M | $-1.8M |
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.4M | ||
| Q2 25 | — | $-1.2M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | — | $-1.2M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $-1.6M | ||
| Q1 24 | $-1.9M | $-1.8M |
| Q4 25 | — | -398.3% | ||
| Q3 25 | — | -205.9% | ||
| Q2 25 | — | -191.5% | ||
| Q1 25 | — | -328.5% | ||
| Q4 24 | — | -246.1% | ||
| Q3 24 | — | -296.1% | ||
| Q2 24 | — | -354.2% | ||
| Q1 24 | -165.0% | -441.2% |
| Q4 25 | — | 3.1% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | — | 7.5% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | — | 3.0% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 8.5% | ||
| Q1 24 | 0.0% | 0.5% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
